Skip to main content
Download PDF
/v1/supplement/title

Correction to: Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial

BMC Infectious Diseases volume 21, Article number: 436 (2021) Cite this article

The Original Article was published on 10 April 2021

Correction to: BMC Infect Dis 21, 337 (2021)

https://0-doi-org.brum.beds.ac.uk/10.1186/s12879-021-06045-3

Following publication of the original article [1], an error was identified in the Abstract section.

The incorrect sentence is: The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/kg/day; control group).

The correct sentence is: The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/day; control group).

The original article has been corrected.

Reference

  1. Ranjbar K, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21:337. https://0-doi-org.brum.beds.ac.uk/10.1186/s12879-021-06045-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Keivan Ranjbar, Mohammad Javad Fallahi, Reza Shahriarirad & Amirhossein Erfani

  2. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

    Keivan Ranjbar, Reza Shahriarirad, Amirhossein Erfani & Mohammad Hasan Gholampoor Saadi

  3. Health Policy research center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran

    Mohsen Moghadami & Alireza Mirahmadizadeh

  4. Non-communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Alireza Mirahmadizadeh

  5. Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

    Mohammad Javad Fallahi & Zohre Khodamoradi

  6. Ali Asghar hospital, Shiraz University of Medical Sciences, Shiraz, Iran

    Vahid Khaloo

  7. Shiraz Geriatric Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Zohre Khodamoradi

Authors
  1. Keivan Ranjbar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohsen Moghadami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alireza Mirahmadizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Javad Fallahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vahid Khaloo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Reza Shahriarirad
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Amirhossein Erfani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zohre Khodamoradi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mohammad Hasan Gholampoor Saadi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohsen Moghadami.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ranjbar, K., Moghadami, M., Mirahmadizadeh, A. et al. Correction to: Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis 21, 436 (2021). https://0-doi-org.brum.beds.ac.uk/10.1186/s12879-021-06130-7

Download citation

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s12879-021-06130-7